Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Neuronetics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Neuronetics's regulatory disclosures and financial reporting.
Neuronetics, Inc. announced a leadership transition in its finance function. On August 11, 2026, Francis X. Brown III’s service as the company’s interim principal financial and accounting officer ended; the company states this change is not due to any dispute or disagreement with him regarding operations, policies, or practices, and he will continue as a consultant. The Board had previously appointed Nir Naor as Executive Vice President, Chief Financial Officer, and Treasurer effective July 23, 2026, and on August 12, 2026, expanded his responsibilities by designating him as principal financial and accounting officer and Corporate Secretary. Neuronetics notes that Mr. Naor received no additional compensation in connection with these expanded roles, discloses that there are no family relationships or arrangements underlying his selection, and states there are no related party transactions requiring disclosure under Regulation S-K Item 404(a).
Neuronetics, Inc. insider Jorey Chernett, a ten percent owner, reported mixed transactions. On 2026-08-14 he purchased 14,000 shares of common stock at a weighted average price of $3.16 per share, in multiple trades between $3.13 and $3.17, bringing his direct holdings to 10,602,988 shares. On 2026-08-13 he sold 100 call option contracts on Neuronetics common stock (underlying 10,000 shares) at $3.21 per option-share with a $5.00 strike price expiring on 2027-02-19, leaving no remaining position in these options. The option sale is described as a matchable transaction under Section 16(b), and Chernett states he intends to disgorge the calculated short-swing profit to Neuronetics. The transactions were not reported as made under a Rule 10b5-1 trading plan.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen report beneficial ownership of common stock of Neuronetics, Inc. The filing covers 3,822,124 shares of common stock, representing 5.0% of the class as of the close of business on August 13, 2026. The reporting persons hold no sole voting or dispositive power, but have shared voting and shared dispositive power over all 3,822,124 shares. The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, under an investment management agreement. The reporting persons state that the filing should not be construed as an admission that any of them is the beneficial owner of these shares for purposes of Section 13 of the Securities Exchange Act.
Neuronetics, Inc. reported higher revenues but continued losses for the quarter and six months ended June 30, 2026. Total revenue was $41.6 million for the quarter, up from $38.1 million, and $76.0 million for the first half of 2026, up from $70.1 million, driven mainly by growth in Greenbrook clinic revenue, which contributed about two-thirds of sales. Gross profit rose to $21.2 million for the quarter and $37.4 million year-to-date, while operating expenses declined, leading to a smaller operating loss.
Net loss attributable to stockholders narrowed to $3.4 million for the quarter and $14.2 million year-to-date, compared with $10.1 million and $22.8 million in the prior-year periods. Operating cash outflow improved to $10.4 million for the first half of 2026, but cash and cash equivalents declined to $19.2 million, with $65.0 million of debt outstanding under the Perceptive Facility. Management discloses substantial doubt about the company’s ability to continue as a going concern due to projected failure of a revenue covenant for the period ending March 31, 2027, which could allow lenders to call the credit facility. Neuronetics raised $7.6 million net through its at-the-market equity program during the quarter and remained in covenant compliance as of June 30, 2026.
Neuronetics, Inc. reported improved second-quarter 2026 results, driven by its Greenbrook clinic network. Total revenue for the three months ended June 30, 2026 was $41.6 million, up 9.1% from $38.1 million a year earlier. Greenbrook revenue rose to $26.9 million, up 16.8%, while NeuroStar revenue declined 2.7% to $14.7 million.
Gross margin expanded from 46.6% to 51.1%, reflecting a new go-to-market strategy and better revenue cycle management at Greenbrook. Operating expenses fell 12% to $22.7 million, reducing loss from operations to $1.5 million from $8.1 million. Adjusted EBITDA turned positive at $0.3 million versus a $5.6 million loss. Net loss narrowed to $3.4 million, or $0.05 per share, from $10.1 million, or $0.15 per share.
As of June 30, 2026, total cash (cash and cash equivalents plus restricted cash) was $25.0 million, down from $34.1 million at December 31, 2025, and long-term debt was $61.5 million. For full-year 2026, the company expects revenue of $160–$164 million (7–10% growth), gross margin between 48% and 50%, operating expenses of $91–$96 million excluding about $4 million of stock-based compensation, and cash flow from operations and investing between $(10.5) million and $(14.5) million.
Neuronetics, Inc. shareholder Jorey Chernett filed Amendment No. 3 to his Schedule 13D, reporting beneficial ownership of 10,588,988 common shares, or 15.22% of the class, based on 69,587,840 shares outstanding as of May 1, 2026. These shares were acquired with personal funds for an aggregate purchase price of approximately $20,682,236, and he holds sole voting and dispositive power over them.
On August 3, 2026, Chernett and Neuronetics reached a “constructive framework for alignment” under which he will have an opportunity to recommend a newly appointed member of the board, subject to customary board approvals and governance processes. Related share transactions and a press release describing the understanding are included as exhibits.
Naor Nir reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. granted its EVP, CFO & Treasurer, Naor Nir, a 500,000-share restricted stock unit (RSU) award of common stock on July 23, 2026. The RSUs vest in four equal installments beginning on July 23, 2027, subject to his continuous employment. Each RSU represents a contingent right to receive one share of Neuronetics common stock, resulting in 500,000 shares reported as directly held after the award.
Neuronetics, Inc. reported that executive Naor Nir, serving as EVP, CFO & Treasurer, submitted an initial statement of beneficial ownership on SEC Form 3. The structured data lists no equity transactions or holdings, and there are no derivative positions disclosed.
Neuronetics, Inc. announced executive leadership changes and related compensation arrangements. The Board appointed Nir Naor as Executive Vice President, Chief Financial Officer, and Treasurer, effective on or about July 23, 2026, under an offer letter providing a $480,000 base salary, a target annual bonus equal to 50% of base salary, and a grant of 500,000 Restricted Stock Units vesting over four years. If terminated without cause or if he resigns for good reason, he is entitled to 12 months of base salary, a prorated target bonus, and continued health coverage. The company also reported that W. Andrew Macan, Executive Vice President, Chief Legal Officer, and Corporate Secretary, will depart on August 15, 2026, receiving a retention bonus of $231,750, vesting of 164,361 RSUs, and a separation payment of $475,087.50 paid over 12 months; his departure is stated not to result from any dispute or disagreement.
Neuronetics, Inc. disclosed that large shareholder Jorey Chernett, a more than ten percent owner, made an open-market purchase of 35,000 shares of Common Stock on 2026-07-14 at a weighted average price of $1.78 per share, increasing his direct holdings to 10,588,988 shares. The shares were bought in multiple trades between $1.77 and $1.79.